Corporate Profile

Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics utilizes its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Stock Quote


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

News Releases

04 Jan '21
Repare Therapeutics to Present at Virtual Investor Conferences in January
CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 4, 2021-- Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,
31 Dec '20
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
CAMBRIDGE, Mass. & MONTREAL, Quebec --(BUSINESS WIRE)--Dec. 31, 2020-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel
17 Dec '20
Repare Therapeutics Added to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Dec. 17, 2020-- Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

Recent Events

More events are coming soon.

Featured Reports